Gamma-Irradiation of Serum for the Inactivation of Adventitious Contaminants

References

1. 1.↵
   US FDA. Points to Consider in the Characterization of Cell Lines Used to Produce Biologics, FDA/CDER, 1993.

   Google Scholar
2. 2.↵
   International Conference on Harmonisation. ICH Q5A (R1). Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95, October 1997.

   Google Scholar
3. 3.↵
   EMEA. Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products. /410/01 Rev. 2 October 2003.

   Google Scholar
4. 4.↵
   1. Nims R.

   Detection of adventitious viruses in biologicals—a rare occurrence. Dev. Biol. 2006, 123, 153–164.

   OpenUrlGoogle Scholar
5. 5.↵
   1. Kerr A.,
   2. Nims R.

   Adventitious viruses detected in biopharmaceutical bulk harvest samples over a 10 year period. PDA J. Pharm. Sci. Technol. 2010, (this volume).

   Google Scholar
6. 6.↵
   1. Chen D.,
   2. Nims R.,
   3. Dusing S.,
   4. Miller P.,
   5. Luo W.,
   6. Quertinmont M.,
   7. Parekh B.,
   8. Poorbaugh J.,
   9. Boose J. A.,
   10. Atkinson E. M.

   Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization—a case study. Biologicals 2008, 36 (6), 393–402.

   OpenUrlCrossRefPubMedGoogle Scholar
7. 7.↵
   1. Dehghani H.,
   2. Rasmussen B.,
   3. Fung V.,
   4. Piper R.,
   5. Gosink J.,
   6. Weaver B.,
   7. Reddy P.

   Case studies of mycoplasma contamination in CHO cell cultures. Proceedings from the PDA Workshop on Mycoplasma Contamination by Plant Peptones; Parenteral Drug Association: Bethesda, MD, 2007; pp 53–59.

   Google Scholar
8. 8.↵
   1. Sofer G.

   Virus inactivation in the 1990s—and into the 21st century. Part 4, Culture media, biotechnology products, and vaccines. Biopharm Int. 2003, 16 (1), 50–57.

   OpenUrlGoogle Scholar
9. 9.↵
   1. Schuurman R.,
   2. van Steenis B.,
   3. van Strien A.,
   4. van der Noordaa J.,
   5. Sol C.

   Frequent detection of bovine polyomavirus in commercial batches of calf serum by using the polymerase chain reaction. J. Gen. Virol. 1991, 72 (11), 2739–2745.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
10. 10.↵
    1. Finney D. J.

    Statistical Methods in Biological Assay; 3rd ed. Griffin: London, 1978; pp 394–401.

    Google Scholar
11. 11.↵
    Chapter 2.6.7. Mycoplasmas. European Pharmacopoeia; 5th ed. (5.4), 2006.

    Google Scholar
12. 12.↵
    1. Willkommen H.,
    2. Scheiblauer H.,
    3. Löwer J.

    Serum and serum substitutes. Virus safety by inactivation or removal. Dev. Biol. Stand. 1999, 99, 131–138.

    OpenUrlPubMedGoogle Scholar
13. 13.↵
    1. Boose J. A.,
    2. Lister D. C.,
    3. Sofer G

    . Virus inactivation in the 1990s—and into the 21st century. Part 6, Inactivation methods grouped by virus. Biopharm Int. 2003, 16 (4), 42–68.

    OpenUrlGoogle Scholar
14. 14.↵
    1. Bender E.,
    2. Fritzche J.,
    3. Bär M.,
    4. Nordheim W.

    The inactivation of mycoplasmas and bacteria in calf serum by 60Co gamma rays (in German). Arch. Exp. Veterinarmed. 1989, 43 (5), 783–788.

    OpenUrlPubMedGoogle Scholar